Click to see the modal popup.

FY 2007 RFA Grant Application Information (RFA)

Application Information Center for Mental Health Services (CSAT)

Request for Applications (RFA) No. TI-07-007
Posting on March 16, 2007
Receipt date: May 1 , 2007
Announcement Type: Initial

Catalogue of Federal Domestic Assistance (CFDA) No
.: 93.243

Key Dates:

Application Deadline

Applications are due by May 1, 2007.

Intergovernmental Review
(E.O. 12372)

Letters from State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.

Public Health System Impact Statement (PHSIS)/Single State Agency Coordination

Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline.

The Substance Abuse and Mental Health Services Administration, Center for Substance Abuse
Treatment is accepting applications for fiscal year (FY) 2007 for the Physician Clinical Support
System for the Treatment of Substance Use Disorders (PCSS) cooperative agreement.  The purpose of this program is to enhance and further develop the current DATA Physician Clinical Support System designed to assist physicians in treating patients dependent on heroin or prescription opioid drugs with FDA approved products containing buprenorphine.

The current SAMHSA-funded PCSS is supported by over 70 mentors, 5 clinical experts and a medical director. The target population for the clinical support system includes primary care physicians, pain specialists, psychiatrists and other non-addiction medical practitioners who treat opioid dependent patients and are less familiar withopioid dependence treatment than addictions specialists.  However, addictions specialists will also be encouraged to participate in the PCSS or serve as mentors for physicians desiring to treat opioid dependent patients with buprenorphine products.
PCSS is one of SAMHSA’s infrastructure programs.  SAMHSA’s Infrastructure Grants support an array of activities to help the grantee build a solid foundation for delivering and sustaining effective substance abuse prevention and/or treatment and/or mental health services.  Awardees may pursue diverse strategies and methods to achieve their infrastructure development and capacity expansion goals.  The plan put forward in the grant application must show the linkages among needs, the proposed infrastructure development strategy, and increased system capacity that will enhance and sustain effective programs and services. 

PCSS cooperative agreements are authorized under Section 509 of the Public Health Service Act, as amended.  This announcement addresses the Drug Addiction Treatment Act of 2000, as amended by the Office of National Drug Control Policy Reauthorization Act of 2006 (Public Law 109-469), hereafter referred to as DATA, and Healthy People 2010 focus area 26 (Substance Abuse).


Eligibility is limited to the national professional medical organizations authorized by the Drug Addiction Treatment Act of 2000 (DATA) to carry out the training of physicians desiring to prescribe and/or dispense FDA approved buprenorphine products for the treatment of addictive disorders.  These are the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association.  Any of these entities may apply individually; they may also apply as a consortium comprised of all or several of the eligible organizations.  If a consortium is formed for this purpose, a single organization in the consortium must be the legal applicant, the recipient of the award, and the entity legally responsible for satisfying the grant requirements.  If a consortium submits an application, the application must include a written agreement outlining the roles and responsibilities of each participating national professional medical organization.  This agreement must be signed by an authorized official of each member of the consortium and attached to the application in Appendix 4 of the RFA, “Roles and Responsibilities of Participating National Professional Medical Organizations.”

Award Information

Funding Mechanism: Cooperative Agreement
Anticipated Total Available Funding: $500,000
Anticipated Number of Awards: 1
Anticipated Award Amount:

Up to $500,000

Length of Project Period: Up to 3 years

Proposed budgets cannot exceed $500,000 in total costs (direct and indirect) in any year of the proposed project.  Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, and timely submission of required data and reports.

Contact Information

For questions on program issues, contact:

Anton C. Bizzell, M.D.
Medical Officer
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Room 2-1067
Rockville, Maryland 20857

For questions on grants management issues, contact:

Kimberly Pendleton
Office of Program Services, Division of Grants Management
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road, Room 7-1097
Rockville, MD 20857
(240) 276-1421

Documents needed to complete a grant application:

Applications that are not submitted on the required application form will be screened out and will not be reviewed.

Download the complete Announcement No. TI-07-007

MS Word Format Download RFA in MS Word format
PDF Format Download RFA in Adobe PDF format

You must respond to the requirements in the RFA in preparing your application.

PHS 5161-1 (revised July 2000): Includes the face page, budget forms and checklist. Applications that are not submitted on the required application form will be screened out and will not be reviewed.

Additional Materials

For further information on the forms and the application process, see Useful Information for Applicants

Additional materials available on this website include:

Last updated: 12/12/2007